Search

Displaying results 921 - 930 of 10000 in total
  1. Drug

    Sulisobenzone

    go.drugbank.com/drugs/DB11185
    Approved

    chemicals, and pharmaceuticals and as an additive for plastics, coatings, and adhesives [L2670]. … It works to filter out both UVA and UVB rays, protecting the skin from sun UV damage [L2153].

    Mixtures: Rayito de Sol, Rayito de Sol
  2. Drug

    Alirocumab

    go.drugbank.com/drugs/DB09302
    ApprovedInvestigational

    diet and statin treatment. … Alirocumab is a biopharmaceutical that obtained FDA approval in July 2015 as a second line treatment for high cholesterol in adults whose LDL-cholesterol (LDL-C) is not controlled by the combination of

    Products: PRALUENT SOLUTION FOR INJECTION IN A PRE-FILLED PEN 75MG/ML, PRALUENT SOLUTION FOR INJECTION IN A PRE-FILLED PEN 150 MG/ML
  3. Drug

    Trolamine

    go.drugbank.com/drugs/DB13747
    ApprovedInvestigational

    Trolamine contains small amounts of diethanolamine and ethanolamine and may also act as an antioxidant against the auto-oxidation of animal and vegetable fats [A27174]. … Trolamine, which is also referred to as triethanolamine (TEA), is a tertiary amine and a triol. It is a bifunctional compound that exhibits both properties of alcohols and amines.

    Categories: Preparations for Treatment of Wounds and Ulcers
  4. Drug

    Carbidopa

    go.drugbank.com/drugs/DB00190
    ApprovedInvestigational

    An individual formulation containing solely carbidopa was generated to treat nausea in patients where the combination therapy [levodopa]/carbidopa is not efficient reducing nausea. … Carbidopa presents a chemical denomination of N-amino-alpha-methyl-3-hydroxy-L-tyrosine monohydrate.

    Mixtures: LEVO C AL 100MG/25MG RET, LEVO C AL 100MG/25MG RET
  5. Drug

    iCo-007

    go.drugbank.com/drugs/DB05268
    Investigational

    iCo-007 (formerly known as ISIS 13650) is a second generation antisense compound being developed by iCo for the treatment of various eye diseases caused by the formation of new blood vessels (angiogenesis … ) such as age-related macular degeneration (AMD) and diabetic retinopathy(DR).

  6. Drug

    Levoleucovorin

    go.drugbank.com/drugs/DB11596
    ApprovedInvestigational

    This important pathway, which is required for de novo synthesis of nucleic acids and amino acids, is disrupted when high-dose methotrexate is used for cancer therapy. … Folic acid is an essential B vitamin required by the body for the synthesis of purines, pyrimidines, and methionine before incorporation into DNA or protein.

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    Doconexent

    go.drugbank.com/drugs/DB03756
    ApprovedInvestigational

    It is an omega-3 fatty acid and primary structural component of the human brain, cerebral cortex, skin, and retina thus plays an important role in their development and function. … It can be biosythesized from alpha-linolenic acid or commercially manufactured from microalgae.

    Mixtures: Protect Cardio AF, VINATAL DHA CAPSULA DE GELATINA BLANDA
  8. Drug

    Phytic acid

    go.drugbank.com/drugs/DB14981
    Investigational

    Phytic acid is under investigation in clinical trial NCT01000233 (Value of Oral Phytate (InsP6) in the Prevention of Progression of the Cardiovascular Calcifications).

    Synonyms: Säure des phytins
  9. Drug

    Crizotinib

    go.drugbank.com/drugs/DB08865
    ApprovedInvestigational

    Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic … Second- and third-generation ALK-tyrosine kinase-inhibitors have overcome many of the pharmacodynamic and genetic resistance mechanisms crizotinib is prone to.

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexProducts: XALKORI 250MG KAPSÜL, 60 ADET, XALKORI 200 MG KAPSUL, 60 ADET
  10. Drug

    Cangrelor

    go.drugbank.com/drugs/DB06441
    ApprovedInvestigational

    Cangrelor is an intravenous, direct-acting, reversible P2Y12 inhibitor for patients undergoing percutaneous coronary intervention (PCI) who have not been yet treated by oral P2Y12 inhibitors. … An advantage Cangrelor provides over oral P2Y12 inhibitors (such as prasugrel, ticagrelor, and clopidogrel) is that it is an active drug not requiring metabolic conversion therefore providing a rapid onset

    Products: KENGREXAL 50 MG ENJEKSİYONLUK/İNFÜZYONLUK ÇÖZELTİ HAZIRLAMADA KULLANILACAK KONSANTRE İÇİN TOZ, 10 ADET